MX2021015514A - Compuesto heterociclico. - Google Patents

Compuesto heterociclico.

Info

Publication number
MX2021015514A
MX2021015514A MX2021015514A MX2021015514A MX2021015514A MX 2021015514 A MX2021015514 A MX 2021015514A MX 2021015514 A MX2021015514 A MX 2021015514A MX 2021015514 A MX2021015514 A MX 2021015514A MX 2021015514 A MX2021015514 A MX 2021015514A
Authority
MX
Mexico
Prior art keywords
heterocyclic compound
formula
present
compound
constipation
Prior art date
Application number
MX2021015514A
Other languages
English (en)
Inventor
Haruhi Ando
Masami Yamada
Ikuo Fujimori
Kazuaki Takami
Kenichiro Shimokawa
Masaki Ogino
Masataka Murakami
Jinichi Yonemori
Tomohiro Okawa
Masaki Seto
Shinobu Sasaki
Tomoko Ohashi
Toshihiro Imaeda
Yasuhiro Tsukimi
Takeshi Wakabayashi
Makoto Fushimi
Tomohiro Ohashi
Hideo Suzuki
Hironobu Maezaki
Ayumu Sato
Yasutomi Asano
Steve Swann
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2021015514A publication Critical patent/MX2021015514A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención tiene como objetivo proporcionar un compuesto que puede ser útil para la profilaxis o tratamiento del estreñimiento y similares. La presente invención proporciona un compuesto representado por la siguiente fórmula (I): (ver Fórmula) en donde cada símbolo es como se describe en la especificación, o una sal del mismo.
MX2021015514A 2017-06-20 2019-12-19 Compuesto heterociclico. MX2021015514A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017120859 2017-06-20
JP2018005960 2018-01-17
US201862683418P 2018-06-11 2018-06-11

Publications (1)

Publication Number Publication Date
MX2021015514A true MX2021015514A (es) 2022-02-22

Family

ID=64737123

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015514A MX2021015514A (es) 2017-06-20 2019-12-19 Compuesto heterociclico.

Country Status (13)

Country Link
US (2) US11236099B2 (es)
DK (1) DK3643718T3 (es)
ES (1) ES2960408T3 (es)
FI (1) FI3643718T3 (es)
HR (1) HRP20231236T1 (es)
HU (1) HUE063823T2 (es)
LT (1) LT3643718T (es)
MX (1) MX2021015514A (es)
PL (1) PL3643718T3 (es)
PT (1) PT3643718T (es)
RS (1) RS64722B1 (es)
SI (1) SI3643718T1 (es)
WO (1) WO2018235838A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018354969B2 (en) * 2017-10-27 2020-09-17 Suven Life Sciences Limited Polycyclic amides as muscarinic M1 receptor positive allosteric modulators
JP7446232B2 (ja) * 2018-09-28 2024-03-08 武田薬品工業株式会社 縮合環化合物
JP7443238B2 (ja) 2018-09-28 2024-03-05 武田薬品工業株式会社 複素環化合物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2992677B2 (ja) 1995-06-05 1999-12-20 武田薬品工業株式会社 骨形成促進医薬組成物
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
JP4710445B2 (ja) * 2004-07-08 2011-06-29 田辺三菱製薬株式会社 医薬組成物
KR101494059B1 (ko) 2009-12-17 2015-02-16 머크 샤프 앤드 돔 코포레이션 퀴놀린 아미드 ｍ1 수용체 양성 알로스테릭 조절제
WO2011159554A1 (en) 2010-06-15 2011-12-22 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide m1 receptor positive allosteric modulators
US8940765B2 (en) 2011-05-17 2015-01-27 Merck Sharp & Dohme Corp. N-linked quinolineamide M1 receptor positive allosteric modulators
EP2821401B1 (en) 2012-03-02 2020-09-09 Takeda Pharmaceutical Company Limited Dihydroquinolinone compounds as modulators of the muscarininc m1 receptor
JP6211530B2 (ja) 2012-11-19 2017-10-11 武田薬品工業株式会社 含窒素複素環化合物
CA2946519C (en) 2014-04-23 2022-07-19 Takeda Pharmaceutical Company Limited Isoindoline-1-one derivatives as cholinergic muscarinic m1 receptor positive alloesteric modulator activity for the treatment of alzheimers disease
WO2015174534A1 (ja) 2014-05-16 2015-11-19 武田薬品工業株式会社 含窒素複素環化合物
WO2015190564A1 (ja) 2014-06-13 2015-12-17 武田薬品工業株式会社 含窒素複素環化合物
WO2016009297A1 (en) * 2014-07-18 2016-01-21 Pfizer Inc. Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
US9878989B2 (en) 2015-06-26 2018-01-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2017069173A1 (ja) 2015-10-20 2017-04-27 武田薬品工業株式会社 複素環化合物
JP2017120859A (ja) 2015-12-28 2017-07-06 帝人株式会社 組紐状圧電素子、組紐状圧電素子を用いた布帛状圧電素子およびそれらを用いたデバイス
US11111251B2 (en) * 2016-02-16 2021-09-07 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M1
JP6860551B2 (ja) 2016-03-11 2021-04-14 武田薬品工業株式会社 芳香環化合物
JP2018005960A (ja) 2016-07-01 2018-01-11 エヌイーシー ショット コンポーネンツ株式会社 接触子を有する気密端子
MX2019002180A (es) * 2016-09-02 2019-08-16 Suven Life Sciences Ltd Moduladores alostericos positivos del receptor m1 muscarinico.
US10899759B2 (en) 2016-09-30 2021-01-26 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M1
EP3612527B1 (en) 2017-04-18 2022-07-20 Takeda Pharmaceutical Company Limited Heterocyclic compounds useful as modulators of acetylcholine receptors

Also Published As

Publication number Publication date
US20220017530A1 (en) 2022-01-20
PL3643718T3 (pl) 2024-01-22
HUE063823T2 (hu) 2024-02-28
ES2960408T3 (es) 2024-03-04
FI3643718T3 (fi) 2023-11-01
LT3643718T (lt) 2023-10-25
RS64722B1 (sr) 2023-11-30
US11236099B2 (en) 2022-02-01
DK3643718T3 (da) 2023-11-06
HRP20231236T1 (hr) 2024-02-16
SI3643718T1 (sl) 2023-11-30
PT3643718T (pt) 2023-10-26
US20210139491A1 (en) 2021-05-13
WO2018235838A1 (ja) 2018-12-27

Similar Documents

Publication Publication Date Title
ZA201701299B (en) Glycosidase inhibitors
SG11201901061QA (en) Heterocyclic compound
MX2018010192A (es) Inhibidores de glucosidasa.
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
MX2018010191A (es) Inhibidores de glucosidasa.
PH12016500225B1 (en) Novel quinoline-substituted compound
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
JO3317B1 (ar) مركبات تترا هيدروبيرولو ثيازين
PH12015501755A1 (en) Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders
PH12016502130B1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
PH12015502611A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
NZ709986A (en) Pharmaceutical compositions comprising nitroxyl donors
MX2019010085A (es) Inhibidores de la glicosidasa de sulfoximina.
MX2021015514A (es) Compuesto heterociclico.
MX2017013880A (es) Derivados del acido tetrahidronaftiridinil propionico y usos de los mismos.
PH12019502248A1 (en) Ip6k inhibitors
PH12015501038A1 (en) Inhibitors of iap
MX2018005004A (es) Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
PH12015502032A1 (en) Azetidinyloxyphenylpyrrolidine compounds
WO2018194181A8 (en) HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS
MY193239A (en) Novel b-lactamase inhibitors
GEP20186893B (en) Pyrazines modulators of gpr6
AU2016363719A8 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
MX2019015747A (es) Compuesto heterociclico.